Prior to empagliflozin initiation | After empagliflozin initiation | P value | |
Drug classes | |||
Metformin, % | 51.1 | 62.2 | <0.001 |
Acarbose, % | 0.5 | 0.5 | 0.781 |
Sulfonylurea, % | 7.4 | 6.1 | 0.055 |
DPP-4 inhibitors, % | 25.8 | 28.3 | 0.035 |
GLP-1 agonists, % | 11.0 | 14.1 | <0.001 |
SGLT2 inhibitors, % | 6.3 | 100 | <0.001 |
Empagliflozin, % | 0 | 100 | <0.001 |
Any other, % | 6.3 | 3.8 | <0.001 |
Insulin, % | 29.3 | 42.4 | <0.001 |
Drug–drug combination therapy | |||
Single drug, % | 27.3 | 26.1 | 0.602 |
Two-drug combinations without insulin, % | 16.6 | 28.3 | <0.001 |
Three-drug combinations without insulin, % | 2.9 | 14.5 | <0.001 |
Combinations including insulin, % | 23.1 | 42.4 | <0.001 |
DPP4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; SGLT-2, sodium-glucose transport protein-2.